What Curida does

Curida AS is a Norway-based pharmaceutical contract development and manufacturing organization (CDMO) specializing in sterile and non-sterile liquid formulations, with core competence in Blow-Fill-Seal (BFS) and nasal spray manufacturing. The company operates three GMP-certified sites in Norway — Elverum (the flagship BFS and nasal spray facility with 6 BFS lines and 4 nasal spray lines producing ~255 million units annually), Fornebu (biologics centre of excellence for monoclonal antibody manufacturing, formerly Diatec), and Ås (small-scale pharmacy formulations, cosmetics and nutrition, formerly Ås Produksjonslab). Founded in 2015 from a 1974-vintage Elverum plant revived by employees, Curida has grown via the 2017 Ås Produksjonslab acquisition and 2019 Diatec Monoclonals acquisition, consolidating three legacy business units under a unified CDMO brand in September 2025.

Curida sells end-to-end CDMO services — formulation, technology transfer (200+ SKUs completed to date under ISPE Good Practice Guide/PMI methodology), fill-finish across BFS, nasal spray, and liquid bottles (glass, LDPE, PET), controlled-drugs manufacturing (including morphine, fentanyl, and cannabis-based medicines), and analytical/microbiological testing — to pharmaceutical, biotech, and diagnostic customers across Europe and globally. The biologics franchise offers monoclonal antibody development, mammalian cell banking using 3L and 50L stirred-tank bioreactors, purification, and bioconjugation (10+ conjugation types) for IVD and clinical supply, serving 40+ diagnostic partners. In October 2025 the company announced a strategic partnership with Rommelag to install Europe's first BFS bottelpack 550 line, adding next-generation capacity and a sustainability-flexible platform to the sterile portfolio.

Curida's revenue model is B2B contract manufacturing services priced by project (formulation, tech transfer, fill-finish, commercial supply), with the customer base spanning academia and start-ups through to Big Pharma, and finished products exported to 80+ countries. Ownership is private and institutional: Signet Healthcare Partners (a US healthcare PE firm) led a 230M-260M NOK growth investment in April 2024 alongside existing Norwegian shareholders Canica, Investinor, Klaveness Marine, and Farvatn Private Equity. The company holds EU GMP, ISO 13485:2016, ISO 9001:2015 certifications, and in February 2026 earned an EcoVadis Bronze Award with a 17-point sustainability score improvement. Financial details, including revenue, are not publicly disclosed.

Name

Curida

Legal name

Curida AS

Website

https://curida.no

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Curida is a Norwegian pharmaceutical CDMO specializing in Blow-Fill-Seal, nasal spray, and biologics contract manufacturing for pharmaceutical, biotech, and diagnostic clients across Europe and 80+ countries. It operates three GMP-certified sites delivering fill-finish, tech transfer, and commercial supply services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Pharmaceutical and Medicine Manufacturing (3254)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Contract pharmaceutical manufacturing
• Blow-fill-seal technology
• Biologics manufacturing services
• Nasal spray manufacturing
• Sterile fill-finish

Headquarters

HQ city

Elverum

HQ country

Norway

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Contract Development and Manufacturing (CDMO) Services: Curida generates revenue through contract manufacturing services for pharmaceutical and biotech companies, providing end-to-end development and manufacturing of liquid pharmaceuticals, biologics, and diagnostic products. Services include formulation, tech transfer, fill-finish, and commercial scale-up under GMP conditions.
2. Pharmacy Formulations Manufacturing: Small-scale manufacturing of pharmaceuticals, cosmetics, and nutrition products for Norwegian pharmacies and clients, including unlicensed pharmaceuticals and compounded products.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Curida is a Norwegian pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end development and contract manufacturing of sterile and non-sterile liquid pharmaceuticals, biologics, and diagnostic products. The company specializes in Blow-Fill-Seal (BFS) and nasal spray manufacturing technologies, delivering services spanning formulation development, tech transfer, fill-finish, analytical testing, and commercial-scale GMP production from facilities in Elverum, Fornebu, and Ås, Norway.

Product overview

Curida is an integrated European CDMO offering end-to-end development and contract manufacturing of biologics and sterile or non-sterile liquid pharmaceuticals. The portfolio centers on three core service areas: Nasal & Ophthalmic Solutions (liquid formulations manufacturing using Blow-Fill-Seal and nasal spray technologies for uni-dose and multi-dose formats), Biologics & Diagnostic Solutions (monoclonal antibody development, manufacturing, and bioconjugation services), and Pharmacy Formulations (small-scale manufacturing for Norwegian pharmacies). Supporting these services are four technology platforms: Blow-Fill-Seal Technology, Nasal Spray Manufacturing, Liquid Bottles & Delivery Systems, and Uni-dose & Multi-dose Formats. A strategic partnership with Rommelag brings Europe's first BFS 550 bottelpack system. The company operates GMP-certified sites across Norway (Elverum, Fornebu, Ås) and serves pharmaceutical and diagnostic partners globally, exporting to over 80 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Curida Biologics: Biologics center of excellence at Technopolis, Fornebu, focusing on monoclonal antibody manufacturing for diagnostics and clinical supply.
• Ås Produksjonslab

Products and services

• Nasal & Ophthalmic Solutions
• Biologics & Diagnostic Solutions
• Pharmacy Formulations
• Tech Transfer Services
• Controlled Drugs Manufacturing
• Bioconjugation Services
• Analytical & Laboratory Services
• Blow-Fill-Seal Manufacturing Technology
• Nasal Spray Manufacturing Technology
• Nasal Sprays & Suspensions

Quantifiable outcome

• 200+ successful SKU tech transfers completed
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered minor and core.

• AFRYminorImplementation/ SI/ Consulting Partner · 1 February 2026Partnership with AFRY to modernize Curida's quality management systems. AFRY implemented a connected, digital eQMS that improves visibility, strengthens data integrity, and supports faster, more informed decision-making for scalable and agile quality foundation.
• RommelagcoreTechnology or Integration · 1 October 2025Strategic partnership with Rommelag, the global leader in Blow-Fill-Seal technology. Curida will become the first company in Europe to install Rommelag's BFS bottelpack 550 system - a next-generation platform designed to deliver greater flexibility, higher output, and enhanced sustainability in sterile liquid manufacturing. The partnership strengthens Curida's position as a European CDMO leader in Nasal & Ophthalmic solutions.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Unither Pharmaceuticals: French-headquartered CDMO specializing in Blow-Fill-Seal sterile single-dose liquid manufacturing for ophthalmic, nasal, and respiratory applications. Most direct comparable to Curida in BFS technology focus, end markets, and customer profile.
• Recipharm (Kindeva): European CDMO with significant sterile fill-finish and Blow-Fill-Seal capabilities serving pharma and biotech customers. Comparable to Curida in CDMO services, geographic base in Europe, and focus on liquid and semi-solid dosage forms.
• Kindeva Drug Delivery: Former 3M Drug Delivery Systems business, now an independent CDMO specializing in inhalation, transdermal, and Blow-Fill-Seal manufacturing. Closely comparable to Curida in BFS expertise and pharmaceutical drug-delivery focus.
• Aptar Pharma: Global leader in drug delivery systems including nasal spray pumps, closures, and dispensing components. Direct overlap with Curida in nasal spray drug delivery, particularly as pharma customers often source both the device and the CDMO fill-finish service.

Broad incumbents

• Catalent: Large global CDMO offering sterile fill-finish, nasal spray, and biologics manufacturing across a broad portfolio. While much larger and broader in scope, Catalent overlaps directly with Curida in nasal spray and aseptic fill-finish CDMO services.
• Aenova Group: European-headquartered CDMO with capabilities in solid, semi-solid, and liquid dosage forms including sterile manufacturing. Comparable to Curida as a European CDMO serving pharma customers with contract manufacturing services.
• Vetter Pharma: German-headquartered CDMO specializing in sterile aseptic fill-finish of injectables and other complex liquid formulations. Comparable to Curida in sterile fill-finish focus, European base, and GMP-certified pharma CDMO positioning.
• Thermo Fisher Scientific (Patheon): Global CDMO offering end-to-end pharmaceutical development and manufacturing services including sterile fill-finish and biologics. Comparable as a broad-based CDMO serving large pharma customers, though far larger and more diversified than Curida.
• Lonza: Swiss-based global CDMO with leading capabilities in biologics manufacturing (mammalian and microbial), as well as small-molecule fill-finish. Comparable to Curida Biologics in monoclonal antibody manufacturing and to the broader CDMO positioning.

Regional players

• Eurofins CDMO: European contract development and manufacturing services arm of Eurofins Scientific, providing API development, biologics, and drug product services. Comparable to Curida in European CDMO positioning with biologics capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/curida

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curida